BIOLASE to Report First Quarter 2024 Results on May 13, 2024

Rhea-AI Summary

BIOLASE, Inc. (NASDAQ:BIOL) will release its first quarter 2024 financial and operating results on May 13, 2024. The company will host a conference call and webcast to discuss the results and corporate developments. Investors can access the live call and archived webcast on the BIOLASE Investor Relations Page.

LAKE FOREST, CA / ACCESSWIRE / May 6, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the globally recognized leader in dental laser technology, today announced that it will release first quarter 2024 financial and operating results on Monday, May 13, 2024, after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and corporate developments.

To access the live call, dial 877-270-2148 (U.S.) or +1 412-902-6510 (International) and ask to join the BIOLASE call.

A live and archived conference call webcast will be accessible on the BIOLASE Investor Relations Page. In addition, a phone replay will be available approximately two hours after the end of the call and will remain available for one week. To access the call replay, dial 877-344-7529 or +1 412-317-0088 (International) and enter replay passcode 4013275.

About BIOLASE

BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals. As of December 31, 2023, BIOLASE's proprietary laser products incorporate approximately 241 active patents and 21 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. From 1998 through December 31, 2023, BIOLASE has sold over 47,700 laser systems in over 80 countries around the world. Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer applications.

For updates and information on Waterlase iPlus^®, Waterlase Express^™, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.

BIOLASE^®, Waterlase^® and Waterlase iPlus^® are registered trademarks of BIOLASE, Inc.

Contacts:
EVC Group, Inc.
Michael Polyviou/Todd Kehrli
(732) 232-6914
mpolyviou@evcgroup.com; tkehrli@evcgroup.com

SOURCE: BIOLASE, Inc.

View the original press release on accesswire.com

FAQ

When will BIOLASE report its first quarter 2024 results?

BIOLASE will report its first quarter 2024 financial and operating results on May 13, 2024.

What time will the conference call and webcast discussing the results take place?

The conference call and webcast will take place on May 13, 2024, at 4:30 p.m. ET / 1:30 p.m. PT.

How can investors access the live call and archived webcast?

Investors can access the live call and archived webcast on the BIOLASE Investor Relations Page.

Is there a phone replay available for the conference call?

Yes, a phone replay will be available approximately two hours after the end of the call and will remain available for one week. Investors can access the call replay by dialing 877-344-7529 or +1 412-317-0088 (International) and entering replay passcode 4013275.